Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENESTnd: Nilotinib vs Imatinib in Newly Diagnosed Ph+ CML-CP
NCT00471497Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2007
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 35
01
Overview
A Phase 3 trial of nilotinib in chronic myeloid leukemia (CML), sponsored by Novartis. Started Jul 2007; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00471497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00471497.